A metabolomics-driven model for early remission prediction following vedolizumab treatment in patients with moderate-to-severe active ulcerative colitis
- Resource Type
- Article
- Source
- In
International Immunopharmacology 15 February 2024 128 - Subject
- Language
- ISSN
- 1567-5769